DANA (depression)
This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| DANA (depression) | |
|---|---|
.png) | |
| Name | DANA (depression) |
| Specialty | Psychiatry, Neurology |
| Symptoms | Mood disturbance, anhedonia, cognitive impairment, sleep disturbance |
| Complications | Suicide, comorbidity with Diabetes mellitus, Coronary artery disease |
| Onset | Variable |
| Duration | Episodic or chronic |
| Causes | Multifactorial |
| Risks | Genetic predisposition, psychosocial stressors |
| Diagnosis | Clinical assessment, standardized rating scales |
| Differential | Bipolar disorder, Schizophrenia, Post-traumatic stress disorder |
| Treatment | Psychotherapy, pharmacotherapy, somatic therapies |
DANA (depression) is a clinical depressive disorder characterized by persistent low mood, diminished interest, and functional impairment across social, occupational, or educational domains. It is diagnosed using standardized criteria and correlates with neurobiological alterations, genetic predisposition, and environmental exposures. Management combines psychotherapy, pharmacological agents, and somatic interventions, with prognosis varying by subtype, comorbidity, and treatment access.
Definition and diagnostic criteria
DANA (depression) is defined by an episode of affective disturbance meeting threshold criteria in diagnostic manuals such as the Diagnostic and Statistical Manual of Mental Disorders and the International Classification of Diseases. Core features include depressed mood, reduced pleasure, changes in appetite or weight, sleep disturbance, psychomotor changes, fatigue, diminished concentration, and suicidal ideation; criteria require symptom persistence and functional impairment as in cases assessed by clinicians from institutions like Mayo Clinic, Johns Hopkins Hospital, and Massachusetts General Hospital. Severity specifiers and remission status align with frameworks used by American Psychiatric Association, World Health Organization, and national guidelines endorsed by bodies such as the National Institute for Health and Care Excellence.
Epidemiology and risk factors
Global prevalence estimates derive from epidemiological surveys like the Global Burden of Disease study and cohorts from Framingham Heart Study, Nurses' Health Study, and the European Study of the Epidemiology of Mental Disorders. Lifetime risk varies across populations including cohorts from United States, United Kingdom, Canada, Australia, and low- and middle-income countries monitored by World Bank datasets. Risk factors encompass heritability evidenced in research from Broad Institute and deCODE genetics, early-life adversity documented by investigators at Harvard T.H. Chan School of Public Health and University College London, chronic medical conditions treated at centers such as Cleveland Clinic, exposure to disasters recorded by United Nations Office for Disaster Risk Reduction, and socioeconomic adversity noted in reports by International Monetary Fund and Organisation for Economic Co-operation and Development.
Pathophysiology and neurobiology
Biological models synthesized by teams at National Institutes of Health, Karolinska Institutet, and Max Planck Society implicate monoaminergic dysregulation, neurotrophic signaling deficits, inflammatory pathways studied by Johns Hopkins Bloomberg School of Public Health, and hypothalamic–pituitary–adrenal axis alterations described in work from Stanford University School of Medicine. Neuroimaging findings from Harvard Medical School, University of Oxford, and University of Toronto show structural and functional changes in the prefrontal cortex, hippocampus, amygdala, and anterior cingulate cortex. Genetic associations reported by consortia like the Psychiatric Genomics Consortium intersect with molecular targets identified at Cold Spring Harbor Laboratory and pharmacological mechanisms explored by pharmaceutical companies including Pfizer, Roche, and Johnson & Johnson.
Clinical presentation and subtypes
Presentation ranges across melancholic, atypical, psychotic, and peripartum subtypes described in clinical series from Cleveland Clinic and Mayo Clinic Department of Psychiatry and Psychology. Melancholic features align with historical descriptions from researchers influenced by work at Kraepelin Institute and case series compiled at Vienna General Hospital. Atypical presentations appear in patient cohorts studied at Karolinska Universitetssjukhuset and University of Barcelona. Comorbid anxiety, substance use, and medical illnesses are reported in registries maintained by Veterans Health Administration, National Health Service (England), and specialty centers such as Sheppard Pratt Health System.
Assessment and diagnostic tools
Diagnostic evaluation uses structured interviews like the Structured Clinical Interview for DSM Disorders and screening instruments such as the Patient Health Questionnaire-9, Beck Depression Inventory, and Hamilton Rating Scale for Depression employed in trials at National Institute of Mental Health and academic centers including Yale School of Medicine and Columbia University Irving Medical Center. Laboratory tests and imaging are adjunctive per protocols from American College of Physicians and specialty guidelines from American Academy of Neurology when ruling out medical mimics. Measurement-based care models advocated by Institute for Healthcare Improvement and outcome registries like those at Kaiser Permanente support routine symptom tracking.
Treatment and management
First-line treatments include psychotherapy modalities such as cognitive behavioral therapy popularized at Beck Institute and interpersonal therapy developed at MCP Hahnemann University, along with pharmacotherapy using classes like selective serotonin reuptake inhibitors prescribed following guidance from Food and Drug Administration approvals and clinical trials run by institutions like University of Pennsylvania and Vanderbilt University Medical Center. For treatment-resistant cases, somatic treatments include electroconvulsive therapy delivered in centers like Bellevue Hospital and Mount Sinai Hospital, repetitive transcranial magnetic stimulation available at Maastricht University Medical Center+, and novel interventions evaluated by trials at Imperial College London and biotech firms such as Neurocrine Biosciences. Collaborative care models integrating primary care teams promoted by World Health Organization and Agency for Healthcare Research and Quality improve accessibility and outcomes.
Prognosis and outcomes
Prognosis depends on episode severity, recurrence risk summarized in longitudinal cohorts like Dunedin Multidisciplinary Health and Development Study and treatment adherence examined in trials from RAND Corporation and Johns Hopkins. Outcomes range from full remission documented in follow-ups at Johns Hopkins to chronicity and functional impairment tracked by Global Burden of Disease metrics. Suicide risk mitigation strategies are prioritized in policies from Centers for Disease Control and Prevention, Samaritans (charity), and national suicide prevention programs coordinated by ministries of health in Japan, Germany, and Brazil.
Category:Mood disorders